Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Revive Therapeutics Ltd. C.RVV

Alternate Symbol(s):  RVVTF

Revive Therapeutics Ltd. is a Canada-based life sciences company. The Company is focused on the research and development of therapeutics for rare disorders and infectious diseases. The Company is exploring the use of Bucillamine for the treatment of infectious diseases, with an initial focus on severe influenza and COVID-19. Through its subsidiary, Psilocin Pharma Corp., the Company is... see more

CSE:RVV - Post Discussion

View:
Post by Grandpaw on Jul 29, 2020 1:04pm

BOOM

Wed Jul 29 02:52:27 2020 EDT
 
July 29 -- Revive Therapeutics (OTCPK:RVVTF) has submitted an IND to the FDA seeking signoff on a confirmatory Phase 3 clinical trial evaluating Bucillamine in patients with mild-to-moderate COVID-19. Unless something unexpected happens, the study will launch in Q3.
 
The primary endpoint of the 800-subject trial is the proportion of patients receiving Bucillamine on top of standard-of-care (SOC) treatment who are alive and hospitalized/not-hospitalized and who have died through day 28 compared to those receiving placebo plus SOC.
 
An interim analysis will be performed after 210 patients have been treated and followed for 28 days.
 
Bucillamine (N-(mercapto-2-methylpropionyl)-l-cysteine) has been marketed for the treatment of rheumatoid arthritis in Japan and South Korea for over 30 years.

Provided by 2016 INTERCONTINENTAL EXCHANGE INC
Comment by KimKWest on Jul 29, 2020 1:09pm
wtf is this?.. dont post old news like this.
Comment by Grandpaw on Jul 29, 2020 1:12pm
READ the DATE
Comment by Chrisxd5 on Jul 29, 2020 1:14pm
Send the link 
Comment by Grandpaw on Jul 29, 2020 1:17pm
Was emailed to me by my broker at PI, copy and pasted that
Comment by KimKWest on Jul 29, 2020 1:20pm
yea send the link bish..what kind of lame a$$ broker would send u one month old news...smh..
Comment by Grandpaw on Jul 29, 2020 1:24pm
Try formulating a response without using the words bish, a$$, etc.  I've been nothing but courteous to you. Not my fault if you cant understand basic chronology, logic, and english.  
Comment by KimKWest on Jul 29, 2020 1:31pm
i have never interacted with you until now. So STFU and stop with the lies. You're posting old news and trying to get everyone attention for no good reason. Lame a$$ bish. Give us some real news not outdated BS.
Comment by Grandpaw on Jul 29, 2020 1:33pm
Ignored.
Comment by Claude75 on Jul 29, 2020 1:37pm
This post has been removed in accordance with Community Policy
Comment by Claude75 on Jul 29, 2020 1:36pm
This post has been removed in accordance with Community Policy
Comment by Grandpaw on Jul 29, 2020 1:38pm
Lol. I have better things to do.  Cut grass wash cars fill boat.  See y'all later. 
Comment by KimKWest on Jul 29, 2020 1:47pm
lol good F off and dont come back you rude bish.
Comment by KimKWest on Jul 29, 2020 1:48pm
eew claudette stfu...why are you s1ut shaming me..you're desperate for action clearly...manchild.
Comment by pinkfloyd90 on Jul 29, 2020 1:18pm
thank you grandpa Walton....goodnight johnboy..goodnight Maryellen.
Comment by KimKWest on Jul 29, 2020 1:19pm
We heard this news one month ago..you idiot. did you just wake up?
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities